Cat. No. | Product name | CAS No. |
DC9586 |
Telatinib
Featured
Telatinib(Bay 57-9352) is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. |
332012-40-5 |
DC5078 |
Tivozanib(AV-951)
Featured
Tivozanib (AV-951, KRN-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 0.21 nM/0.16 nM/0.24 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met EGFR and IGF-1R. |
475108-18-0 |
DC3134 |
Vandetanib (ZD6474)
Featured
Vandetanib (Zactima, ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM. |
443913-73-3 |
DC7607 |
Vatalanib
Featured
Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 1/2. |
212141-51-0 |
DC8655 |
Vatalanib free base
Vatalanib free base (PTK787 free base) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. |
212141-54-3 |
DC11268 |
VEGFR2 kinase inhibitor I(SU-5408)
Featured
VEGFR2 kinase inhibitor I(SU-5408)is a potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM). |
15966-93-5 |
DC1097 |
XL-184 (Cabozantinib,BMS907351)
Featured
XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively. |
849217-68-1 |
DC8871 |
ZM 323881 HCl
ZM 323881 hydrochloride is a potent and selective inhibitor of human Flk-1 (vascular endothelial growth factor receptor 2, VEGFR-2/KDR) activity. |
193001-14-8 |
DC1082 |
ZM306416
Featured
ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist. |
690206-97-4 |
DC1083 |
ZM323881 hydrochloride
ZM323881 a receptor tyrosine kinase inhibitor of VEGFR-2 (Flk-1), PDGFR-beta, EGFR, and FGFR1 |
193000-39-4 |
DC12371 |
XL-999(Tyrosine kinase-IN-1)
Featured
XL999, a Spectrum Selective Kinase Inhibitor(TM) (SSKIs), is a potent inhibitor of key RTKs implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells. |
705946-27-6 |
DC28172 |
Telatinib mesylate
Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively. |
332013-26-0 |
DC28991 |
Sitravatinib malate
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment. |
2244864-88-6 |
DC40160 |
TIE-2/VEGFR-2 kinase-IN-1
TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis. |
453590-24-4 |
DC40575 |
VEGFR-2-IN-6
VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110. |
444731-47-9 |
DC40578 |
CP-547632 TFA
CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. |
|
DC40853 |
SU5208
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2). |
62540-08-3 |
DC41110 |
VEGFR-2-IN-5 hydrochloride
VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69. |
|
DC42426 |
(Z)-Orantinib
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. |
210644-62-5 |
DC42427 |
SU5204
SU5204, a tyrosine kinase extracted from patent US5792783A, has IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively. |
186611-11-0 |
DC45294 |
5α-Hydroxycostic acid
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways. |
132185-83-2 |
DC46126 |
Axitinib-d3
Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. |
1126623-89-9 |